John Marshall

John Marshall at Georgetown University is a longtime leader in clinical colorectal cancer research who has contributed to multiple landmark trials defining first-line chemotherapy regimens including FOLFOX, FOLFIRI, and bevacizumab combinations. His clinical trial work has included TREE and BOND series trials that shaped the early bevacizumab era in CRC. He has been an educator and advocate in the colorectal cancer community and has led educational initiatives to improve CRC outcomes through better biomarker-guided therapy. His expertise spans the full treatment continuum of advanced CRC from first-line to refractory settings.